Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Receivables (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Receivables data on record, last reported at $119.3 million in Q4 2025.

  • For Q4 2025, Receivables rose 28.54% year-over-year to $119.3 million; the TTM value through Dec 2025 reached $119.3 million, up 28.54%, while the annual FY2025 figure was $119.3 million, 28.54% up from the prior year.
  • Receivables reached $119.3 million in Q4 2025 per CAI's latest filing, up from $36.6 million in the prior quarter.
  • Across five years, Receivables topped out at $119.3 million in Q4 2025 and bottomed at $36.6 million in Q3 2025.